source
- Kodiak Sciences' Zenkuda shows non-inferior six-month dosing vs Eylea, shares doubleFour years ago Kodiak Sciences saw its share price plunge about 80% after its lead eye-disease candidate failed a head-to-head trial against Regeneron's Eylea, wiping out roughly $2 billion in mark…
- BMO sees Merck better positioned than BMS to handle looming patent cliffsBMO Capital Markets says Merck has a stronger plan than Bristol Myers Squibb to replace revenue lost to upcoming patent expirations. The firm highlights Merck's pipeline as more derisked and sizabl…